News coverage about Penumbra (NYSE:PEN) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Penumbra earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.0270061990657 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Penumbra from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. BMO Capital Markets increased their price target on Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. Canaccord Genuity restated a “buy” rating and issued a $113.00 price target on shares of Penumbra in a report on Wednesday, January 24th. Finally, JPMorgan Chase & Co. downgraded Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $111.50.
Penumbra (PEN) traded up $1.10 during mid-day trading on Wednesday, hitting $93.60. The stock had a trading volume of 155,608 shares, compared to its average volume of 300,352. The firm has a market capitalization of $3,107.08, a PE ratio of -425.45, a P/E/G ratio of 98.09 and a beta of 0.19. Penumbra has a 52 week low of $74.15 and a 52 week high of $116.35.
In other news, Director Thomas Wilder sold 345 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $91.15, for a total transaction of $31,446.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Arani Bose sold 47,136 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $105.15, for a total value of $4,956,350.40. Following the transaction, the insider now directly owns 700,815 shares of the company’s stock, valued at $73,690,697.25. The disclosure for this sale can be found here. Insiders have sold 295,230 shares of company stock valued at $29,788,550 over the last ninety days. 13.50% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/15/penumbra-pen-earns-media-sentiment-rating-of-0-23.html.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.